Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add filters








Language
Year range
1.
J Indian Med Assoc ; 2022 Aug; 120(8): 17-22
Article | IMSEAR | ID: sea-216592

ABSTRACT

Introduction : A disseminated disease with positive Blood Culture during the first month of life and encompasses various systemic infections of the newborn such as septicemia, meningitis, pneumonia, arthritis, osteomyelitis and Urinary Tract Infection is defined as Neonatal Sepsis. It is one of the leading causes of morbidity and mortality amongst neonates of developing countries. Aim : To determine the microbial profile of Blood Culture-positive Septicemia cases and study their antimicrobial susceptibility pattern. Materials and Methods : Blood Culture and C-reactive Protein (CRP) estimation were done for all 220 clinically suspected neonates. All the pure Bacterial and Candida isolates were identified using standard biochemical tests. Antimicrobial susceptibility testing was done for all bacterial isolates using the Kirby-Bauer disk diffusion method as per Clinical and Laboratory Standards Institute (CLSI) guidelines. Results : Out of 220 cases, 68.2% were culture positive. Early-onset Neonatal Septicemia (EONS) cases were 74% and Late-onset Neonatal Septicemia (LONS) 26%. The male to female ratio was 1.9:1. Bacterial cases were 66% and 34% were due to Candida. Gram-negative isolates predominated, with Klebsiella pneumonia being the most common one. In the case of Gram-positive isolates, Staphylococcus aureus was most common. The best overall sensitivity of Gram-negative isolates was to Amikacin (100%), Colistin (100%), and Imipenem (96%). Grampositive isolates reported 100% sensitivity to Vancomycin, Teicoplanin and 97.4% to Linezolid. Conclusion : Gram-negative isolates were the leading cause of Sepsis in our study. Strict antimicrobial stewardship should be implemented to prevent the emergence of multi-drug resistant strains.

2.
Article in English | IMSEAR | ID: sea-153870

ABSTRACT

Any damage at molecular or cellular level is the major culprit for disease & ill health. Nanotechnology, “the manufacturing technology of the 21st century," helps us economically build a broad range of complex molecular machines by manipulating matter on an atomic and molecular scale. Nanotech may be able to create many new materials and devices with at least one dimension sized from 1 to 100 nanometres with a vast range of applications, such as in medicine, electronics, biomaterials and energy production. Lots of new possibilities come into account in relation to use of nanotechnology in medicines. Nanotechnology in medicine involves applications of nanoparticles, also involves nano-robots to make repairs at the cellular levels. On the other hand, nanotechnology raises many of the same issues as any new technology, including concerns about the toxicity and environmental impact of nanomaterials.

SELECTION OF CITATIONS
SEARCH DETAIL